FOLLOW US:
___________

  • About
    • Steering Committee
    • Secretariat
    • Annual Reports
    • History
    • Sponsors
      • Sponsor Agreement
  • Get Involved
    • Projects
    • Conferences
  • Call to Action
    • Call to Action 2021-2022
    • Call to Action 2019-2020
    • Call to Action 2017-2019
    • Call to Action 2015-2016
    • Call to Action 2012-2014
    • Call to Action 2010-2011
  • Projects & Collaborations
    • European Testing Week
    • INTEGRATE
    • OptTEST
    • Late Presentation for Viral Hepatitis
    • Late Presentation of HIV / Infected not yet Diagnosed
    • Indicator Condition Guided HIV Testing/HIDES
      • HIV Testing Audit Tool
      • Guidance: HIV Indicator Conditions
    • Stigma Index
    • Hepatitis B and C
    • Evidence and Practice of HIV Counselling
    • Development of the ECDC Testing Guidance for hepatitis B, hepatitis C and HIV
    • Evaluation of the 2010 ECDC HIV Testing Guidance
    • Monitoring and Evaluation of HIV testing Efforts
    • COVID-19 impact assessment on testing
  • Conferences
    • HepHIV 2023 Madrid Conference
      • Organising Committee
      • Venue
    • HepHIV 2021 Lisbon & Virtual Conference
      • Scientific Programme
      • Presentations
        • Opening Session
        • Plenary Session 1: Special Session: Impact of COVID-19 on prevention and testing services for HIV, viral hepatitis, STIs and TB: Building back better
        • Abstract Driven Session1: The use of new technologies to increase testing coverage
        • Plenary Session 2: Combination prevention in HIV, viral hepatitis, STIs and TB
        • EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action
        • Plenary Session 3: Implementing integrated testing strategies
        • Abstract Driven Session 2: Models of testing and linkage to care for PWID and PWUD
        • Plenary Session 4: Special Session: People who inject/use drugs (EMCDDA/ECDC)
        • Closing Session: Integrating disease areas and settings
        • Poster Session 1 (PO1): Innovative testing services during the COVID-19 pandemic: lessons learned
        • Poster Session 2 (PO2): Impact of COVID-19 on provision of services for people who inject/use drugs
        • Poster Session 3 (PO3): New testing technologies to increase testing coverage: HIV self-testing and home-based sampling
        • Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings
        • Poster Session 5 (PO5): Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings
        • Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs
      • Side Meetings
      • Conference Objectives
      • Organising Committee
      • Newsletters
      • Auspices and Endorsers
      • Sponsors
      • For Press
    • HepHIV 2019 Bucharest Conference
      • Conference Objectives
      • Organising Committee
      • Scientific Programme
      • Presentations
        • Posters
          • Poster Category 1: Monitoring and Evaluation
          • Poster Category 2: Combination Prevention
          • Poster Category 3: Integrated Testing Strategies
          • Poster Category 4: Linkage to Care
        • Opening Session: Challenges of Timely and Integrated Testing and Care
        • Plenary Session 1: Epidemiological and Testing Policy Overview: Where are we in reaching the targets?
        • Plenary Session 2: Combination prevention
        • Plenary Session 3: Linkage to care and treatment for better outcomes: Good models and challenges
        • Plenary Session: Fast track cities initiatives: How to expand to other disease areas
        • Plenary Session: EU Health Project Symposium: Integrated Testing and Synergies
        • Plenary Special Session: The elimination of HIV and hepatitis agenda: What needs to be done?
        • Closing Session: Integration of services
        • Parallel Session 1: Monitoring and Evaluation
        • Parallel Session 2: Combination Prevention
        • Parallel Session 3: Integrated Testing Strategies
        • Parallel Session 4: Linkage to Care
      • HepHIV2019 Newsletters
      • Venue
      • Official Patronage & Endorsers
      • Sponsors
      • Scholarships
      • Photo Gallery
        • HepHIV2019 - Monday
        • HepHIV2019 - Tuesday
        • HepHIV2019 - Wednesday
    • HepHIV 2017 Malta Conference
      • HepHIV2017: Call to Action
      • Presentations
        • Opening Session
        • Plenary Session 1: Surveillance and monitoring and evaluation of testing
        • Plenary Session 2: Mixing testing strategies: Community and health care..
        • Special Session on PrEP: Influence of PrEP and new treatment paradigms ...
        • Plenary Session 3: Continuum of Care and improving linkage to care
        • Plenary Session 4: New point of care diagnostics, affordability and ..
        • Parallel Session 1: Monitoring for HIV and viral hepatitis
        • Parallel Session 2: Testing strategies in key affected populations
        • Parallel Session 3: Challenges in health care settings: Testing and linkage ...
        • Parallel Session 4: Community testing
        • Closing session
        • Poster Category 1: Monitoring for HIV and Viral Hepatitis
        • Poster Category 2: Testing Strategies in Key Affected Populations
        • Poster Category 3: Challenges in Health Care Settings and Linkage to Care
        • Poster Category 4: Community Testing
      • Scientific programme
      • Scholarships
      • Organising Committee
      • Sponsors and endorsers
      • Photo Gallery
    • HepHIV 2014 Barcelona Conference
      • HepHIV2014: Call to Action
      • Conference objective
      • Presentations
        • Opening session
        • PLE1: What´s the status of the continuum of care in HIV and viral hepatitis?
        • PLE3: Testing strategies in HV and viral hepatitis: new innovative approaches
        • PLE4: Linkage to care and economic consequences
        • PLE5: Testing and linkages to care in key populations
        • Closing session
        • PS1: Late presentation
        • PS2: Testing in health care settings
        • PS3: Key populations 1
        • PS4: Key populations 2
        • PS5: The treatment cascade
        • PS6: Alternative approaches
        • PO1/PS1: Late presentation
        • PO2/PS2: Testing in health care settings
        • PO3/PS3/PS4: Key populations
        • PO4/PS5: The treatment cascade
        • PO5/PS6: Alternative approaches
      • Scientific programme
      • Scholarships
      • Organising committee
      • Sponsors
    • Copenhagen Conference 2012
      • Copenhagen2012: Call to Action
      • Conference Objective
      • Presentations
        • Opening Session
        • Plenary - Access to earlier Testing and Care
        • Plenary - Late presenters and the undiagnosed
        • Plenary - Discussing testing strategies
        • Panel Discussion: HIV in Europe - the way forward
        • Parallel session 1
        • Parallel session 2
        • Parallel session 3
        • Parallel session 4
        • Parallel session 5
        • Parallel session 6
        • Poster category 1
        • Poster category 2
        • Poster category 3
        • Poster category 4
        • Poster category 5
        • Poster category 6
        • Poster category 7
        • Poster category 8
        • Poster category 9
        • Poster category 10
      • Scientific Programme
      • Scholarships
      • Sponsors
      • Pictures from Copenhagen 2012 Conference
    • Stockholm Conference 2009
      • Presentations
      • Reports
    • Brussels Conference 2007
  • Publications & Presentations
    • Presentations
    • Publications
  • Testing Tools
    • Integrated testing in health care settings
      • HIV Indicator Conditions
    • Integrated testing in community and low-threshold settings
    • Self-testing and self-sampling
  • News
    • Latest Publications & Outcomes
    • Newsletters
Conferencesbreadcrumb separatorHepHIV 2021 Lisbon & Virtual Conferencebreadcrumb separatorPresentationsbreadcrumb separatorAbstract Driven Session 2: Models of testing and linkage to care for PWID and PWUD

 

 

AS2/01 Testing and linkage to care services for 1000 people who inject drugs from Bucharest through the implementation of a three level HCV elimination strategy
Raluca Teodorescu

AS2/02 Integrated harm reduction responses to HIV and viral hepatitis in the COVID-19 pandemic: a global overview
Sam Shirley-Beavan

AS2/03 Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan, Italy
Sara Mazzilli

AS2/04 Blood-borne virus testing in people who inject drugs with a history of sex work
Eva Emanuel

AS2/05 HCV care for PWID in Europe - results from a civil society-led monitoring
Rafaela Rigoni

Live Discussion

 

 

COORDINATION SECRETARIAT


Rigshospitalet, University of Copenhagen
CHIP, Department of Infectious Diseases
Section 2100, Finsencentret
Blegdamsvej 9
DK-2100 Copenhagen Ø
Denmark
Tel: +45 35 45 57 57
Fax: +45 35 45 57 58
Email: eurotest.rigshospitalet@regionh.dk

ADVOCACY SECRETARIAT


Ann Isabelle von Lingen, Policy Officer
European AIDS Treatment Group (EATG)
Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium
Tel 32 2 626 96 41
M+32 491348317
Fax 32 2 644 33 07
annisabelle.vonlingen@eatg.org